The Drill Down

Ep. 46: Ansys with Bokeh Capital’s Kim Forest, ChemoCentryx, IBM,

July 6, 2021

Will a new amendment filing on their New Drug Application be enough of a boost for ChemoCentryx (CCXI)? Why IBM (IBM) can’t get its own email system on the cloud under control. How’s (BKNG) underwater $500M investment in DiDi Global could sink even deeper. Plus, Kim Forest of Bokeh Capital tells us what multiphysics software company Ansys (ANSS) is planning for the future of software. The Drill Down with Cory Johnson offers a daily look at the business stories behind stocks on the move.

Podbean App

Play this podcast on Podbean App